BillionaireClubCollc
  • News
  • Notifications
  • Shop
  • Cart
  • Media
  • Advertise with Us
  • Profile
  • Groups
  • Games
  • My Story
  • Chat
  • Contact Us
home shop notifications more
Signin
  •  Profile
  •  Sign Out
Skip to content

Billionaire Club Co LLC

Believe It and You Will Achieve It

Primary Menu
  • Home
  • Politics
  • TSR
  • Anime
  • Michael Jordan vs.Lebron James
  • Crypto
  • Soccer
  • Dating
  • Airplanes
  • Forex
  • Tax
  • New Movies Coming Soon
  • Games
  • CRYPTO INSURANCE
  • Sport
  • MEMES
  • K-POP
  • AI
  • The Bahamas
  • Digital NoMad
  • Joke of the Day
  • RapVerse
  • Stocks
  • SPORTS BETTING
  • Glamour
  • Beauty
  • Travel
  • Celebrity Net Worth
  • TMZ
  • Lotto
  • COVD-19
  • Fitness
  • The Bible is REAL
  • OutDoor Activity
  • Lifestyle
  • Culture
  • Boxing
  • Food
  • LGBTQ
  • Poetry
  • Music
  • Misc
  • Open Source
  • NASA
  • Science
  • Natural & Holstict Med
  • Gardening
  • DYI
  • History
  • Art
  • Education
  • Pets
  • Aliens
  • Astrology
  • Farming and LiveStock
  • LAW
  • Fast & Furious
  • Fishing & Hunting
  • Health
  • Credit Repair
  • Grants
  • All things legal
  • Reality TV
  • Africa Today
  • China Today
  • "DUMB SHIT.."
  • Stocks

GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines

Idrees Abbas / SOPA Images / LightRocket via Getty Images

Key TakeawaysGSK has purchased the rights to COVID-19 and flu vaccines being developed in collaboration with German biotechnology company CureVac.GSK said it will pay CureVac as much as $1.56 billion to assume full control of the treatments.The companies have been working together on mRNA vaccines since 2020.
Drug maker GSK (GSK) agreed to pay up to $1.56 billion for the rights to develop, manufacture, and market COVID-19 and influenza vaccines being worked on in collaboration with German biotechnology company CureVac (CVAC).GSK said CureVac would receive EUR400 million ($432 million) up front, and up to an additional EUR1.05 billion ($1.13 billion) in development, regulatory, and sales milestones.The companies teamed up during the COVID-19 outbreak in 2020 to create mRNA vaccines for infectious diseases. GSK said its efforts have produced “candidates for seasonal influenza and COVID-19 in phase II and avian influenza in phase I clinical development” based on CureVac’s mRNA technology. The updated deal means GSK will “assume full control of developing and manufacturing these candidate vaccines," the company said.CureVac Shares Rise After Deal AnnouncementCureVac shares initially rose on the announcement Wednesday, but dropped by 5% near closing in Independence Day holiday-shortened trading. The deal "puts us in a strong financial position and enables us to focus on efforts in building a strong R&D pipeline," said Chief Executive Officer Alexander Zehnder.The news came a day after Moderna (MRNA) received a $176 million U.S. government grant to come up with a vaccine to prevent avian flu in humans. GSK's American depositary receipts (ADRs) are up about 3.6% year-to-date. They were slightly higher at $38.40 near early closing on Wednesday.

TradingView

Read the original article on Investopedia.

Welcome to Billionaire Club Co LLC, your gateway to a brand-new social media experience! Sign up today and dive into over 10,000 fresh daily articles and videos curated just for your enjoyment. Enjoy the ad free experience, unlimited content interactions, and get that coveted blue check verification—all for just $1 a month!

Source link

Share
What's your thought on the article, write a comment
0 Comments
×

Sign In to perform this Activity

Sign in
×

Account Frozen

Your account is frozen. You can still view content but cannot interact with it.

Please go to your settings to update your account status.

Open Profile Settings

Ads

  • Premium Billionaire128 Women’s Racerback Tank

    $ 24.50
  • Original Billionaire128 Basic Pillow

    $ 26.50
  • Billionaire128 Liquid Gold Bean Bag Chair COVER

    $ 70.00
  • News Social

    • Facebook
    • Twitter
    • Facebook
    • Twitter
    Copyright © 2024 Billionaire Club Co LLC. All rights reserved